• Medical_Professionals
• Medical_students
• Nurses

Providing state-of-the-art cancer care through diagnostic, therapeutic, and supportive strategies is dependent on incorporating the latest clinical advancements and data into practice. In solid tumors and hematologic malignancies alike—and across all cancer types—novel approaches in testing, systemic therapy, targeted and immunotherapies, and combination strategies continue to drive improvements in patient outcomes.

Now in its 35th year, the Chemotherapy Foundation Symposium™ (CFS™) brings together more than 2000 healthcare professionals, including oncologists, hematologists, radiologists, immunologists, pharmacists, NPs, PAs, and patient advocates, and strives to deliver the latest answers to your clinical challenges. Our internationally renowned faculty will provide expert analysis on the most recent developments in cancer therapies, synthesizing scores of data to provide attendees with the critical distilled information they need. This preeminent 3-day conference provides an unparalleled opportunity to learn new methods of personalizing care for your patients with cancer. Together, we will Innovate Cancer Therapy for Tomorrow®. See you in New York!

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca, Boehringer Ingeheim Pharmaceuticals, Inc., Celgene Corporation, Daiichi Sankyo, Inc., Eisai, Inc., Exelixis, Ignyta, Incyte Corporation, Ipsen Biopharmaceuticals, Inc., Lilly, Novartis Pharmaceuticals Corporation, Novocure, Pharmacyclics LLC, an AbbVie Company, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, Taiho Oncology, and Takeda Oncology.

Target Audience

This educational activity is directed toward oncologists, hematologists, nurses, nurse practitioners, and pharmacists interested in the treatment/management of patients with cancer. Radiotherapists, immunologists, fellows, physician assistants, researchers, case managers, and other healthcare professionals interested in the treatment of cancer are also invited to attend.

Learning Objectives

Upon completion of this activity, participants should be better prepared to:

Determine the most appropriate testing strategies to stratify risk and inform clinical decision-making in the management of cancer

Describe important clinical trial results that inform treatment practices and are altering care paradigms for patients with hematologic malignancies and solid tumors

Identify immunotherapeutic, chemotherapeutic, and targeted approaches demonstrated by recent evidence to optimize clinical outcomes

Delineate methods multidisciplinary teams can proactively apply to prevent and mitigate the impact of treatment-related toxicities findings in the context of evolving treatment pathways to improve care for patients with cancer

Assess practice-changing evidence and apply these findings in the context of evolving treatment paradigms to optimize the care of patients with cancer

Adam M. Brufsky, MD, PhD

Professor of Medicine

Associate Chief, Division of Hematology/ Oncology

Co-Director, Comprehensive Breast Cancer Center Associate

Director, Clinical Investigation

University of Pittsburgh

Pittsburgh, PA

Benjamin Levy, MD

Clinical Director of Medical Oncology

Johns Hopkins Sidney Kimmel Cancer Center

Sibley Memorial Hospital

Washington, DC

William Oh, MD

Chief, Division of Hematology and Medical Oncology

Professor of Medicine and Urology

Ezra M. Greenspan, MD Professor in Clinical Cancer Therapeutics

Icahn School of Medicine at Mount Sinai

Associate Director of Clinical Research

The Tisch Cancer Institute

New York, NY

USD

Group registrations not allowed

Accompanying persons not allowed

We don’t accept Online Abstracts

New York Marriott Marquis

1535 Broadway

New York, NY 10036

Reservations: (800) 843-4898 | Book Online

A limited block of rooms has been set aside at the New York Marriott Marquis at a run-of-house rate of $397 (single/double) plus applicable state and local taxes. Rates and rooms are subject to availability at the time of the reservation.

To make a reservation, call (800) 843-4898 or book online. The deadline for making your hotel reservations is October 27, 2017. After that date, or in the event that the room block becomes full prior to the deadline, rooms are subject to availability, and the room rates may increase. When booking, please mention the CFS™ to receive the discounted group rate. All reservations must be accompanied by a first night room deposit or guaranteed with a major credit card.

All reservations must be accompanied by a first night room deposit or guaranteed with a major credit card. The hotel will not hold any reservations unless secured by one of the above methods.

Physicians’ Education Resource® (PER®) recommends that you make your airline reservations early to get the best seat options and lowest airfare available. The gateways to the NYC area are LaGuardia Airport (LGA, 9.5 miles) and John F. Kennedy International Airport (JFK, 18.5 miles) in NY, and Newark Liberty International Airport located in NJ (EWR, 16.5 miles).

You are invited to make your travel arrangements through PER’s travel partner, Singer Travel, at (610) 378-1610 between 9:00 am and 5:30 pm Eastern Standard Time. Please ask for Jill Schuler.

Groups of 10 or more physicians are eligible for a discount on registration!

Book your group today and receive a $100.00* discount off the physician registration rate! Contact Ana Monte, Ana.monte@marriott.com, to set up an affiliate hotel room block with the Marriott Marquis. Once the hotel room block is complete, a member of the PER staff will be in contact to register your group and provide confirmation. For more information, contact info@gotoper.com.

Submission Info

35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®— Call for Poster Abstracts!

The Program Chairs and Steering Committee invite you to submit your abstracts for the 35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®, to be held November 8-10, 2017, at the New York Marriott Marquis in Times Square, New York, NY.

Deadline for submission is August 29, 2017, at 11:59 am EDT.

**Please note the EDT time zone and morning submission deadline.

All poster abstract submissions must be made electronically through the PER® online abstract submission system.

The abstract should be a short description of your work and should contain all the elements necessary to define your goals and results to the reader, and include the components of the abstract body listed below. Authors will be required to disclose all financial relationships through the online system, helping to ensure quality and unbiased presentations. However, the formal poster session is not designated for credit. 

Share your research or best practices with your peers. Categories of submission include:

Hematologic Malignancies Gastrointestinal Cancers

Gynecologic Malignancies

Head and Neck Cancers

Oncology Informatics

Central Nervous System Tumors, Neuroendocrine Tumors

Breast Cancers

Soft Tissue Sarcoma

Lung Cancers

Melanoma and other Cutaneous Malignancies

Genitourinary Malignancies

Immunotherapies

Targeted Therapies, Regional Therapies, Chemotherapies

Personalized and Precision Medicine

Biomarkers, Testing, Sequencing

Survivorship, Patient Care Management, Team-Based Care

Clinical Trials

Healthcare Reform, Value-Based Care, Clinical Pathways

Other

The Program Chairs and Steering Committee will evaluate the scientific quality of the submitted abstracts based on the following criteria: novelty of the research, significance of the findings, and clarity. Incomplete abstracts will not be reviewed.

Notification of acceptance or regret will be delivered via e-mail to the presenters of each poster abstract by mid-September. Please note that an author is required to be present during the poster session.

If accepted for presentation, abstracts and posters will be available for viewing online on the 2017 Chemotherapy Foundation Symposium website during and after the conference. A formal poster viewing will be held during the conference in the Exhibit Hall, where breakfast and refreshment breaks will also be held. The presentation at the conference should reflect the submitted abstract; abstract title, authorship, and content of the presentation must match the submitted abstract.

All presenters must register to attend the 35th Annual Chemotherapy Foundation Symposium. Please visit www.gotoper.com to register.

Submission Process

Complete the abstract template provided on the 2017 Chemotherapy Foundation Symposium website.

Limit is 2500 characters (abstract body, including spaces and table). 

Upload full abstract or poster where prompted.

Components of the abstract body – Limit: 2500 characters (1 table allowed)

Background/Significance — What was the problem and why was it important? What knowledge are you building on? What was the intent or goal of the study? What did you want to learn?

Materials and Methods — What was the trial design? What was the sample? What instruments were used? How were data collected and analyzed?

Results — What were the findings?

Conclusions — What do the findings mean?

FAQ

TIP abstracts are accepted.

Encore abstracts are accepted.

Abstract Questions

Please submit any questions pertaining to abstract submissions to abstracts@gotoper.com using the subject line “CFS Abstract QUESTION.”

Author Consent and Waiver of Claims

Each Abstract Author agrees and certifies that he or she:

Waives any and all claims against Physicians’ Education Resource®, LLC, sponsor of the 35th Annual Chemotherapy Foundation Symposium, and any reviewer arising out of or relating to the abstract submission and review process, including but not limited to peer review and the grading of abstracts.

Abstract submission deadline 2018-06-12

New York, NY

1535 Broadway

New York, NY 10036

888-523-0366

New York, NY

1535 Broadway

New York, NY 10036

888-523-0366